Please assess the completion status of the following clinical trial:

Trial Title: A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is obese with a BMI ≥35 to ≤45 kg/m2.~* Has stable body weight (not varying by \>5% within 3 months prior to study start).~* Meets certain requirements with respect to concomitant medications.~* Has not smoked or used nicotine-containing products for at least 12 months prior to study start.~Exclusion Criteria:~* Has not been enrolled in a weight loss program within 2 months prior to study start.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Pramlintide+Metreleptin
- Group B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).